Standout Papers

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment 2014 2026 2018 2022 363
  1. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment (2014)
    E. Blind, Kristina Dunder et al. New England Journal of Medicine

Immediate Impact

21 by Nobel laureates 11 from Science/Nature 64 standout
Sub-graph 1 of 23

Citing Papers

Transforming obesity: The advancement of multi-receptor drugs
2024 Standout
Postmenopausal Osteoporosis
2023 Standout
3 intermediate papers

Works of E. Blind being referenced

Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective
2018
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
2014 Standout

Author Peers

Author Last Decade Papers Cites
E. Blind 385 424 232 459 46 1.1k
Tomaž Kocjan 215 274 280 360 50 1.2k
Marcello Filopanti 150 499 258 450 40 1.3k
P. Clifton‐Bligh 227 198 179 324 54 1.1k
Hao Ly 154 635 285 210 27 1.2k
Chunjun Sheng 209 359 62 525 35 1.0k
W. J. Henderson 166 254 203 211 35 913
V Pacovský 370 383 129 361 45 1.1k
P. M. Jehle 192 320 104 349 41 995
Barbara Toffoli 168 549 56 216 45 1.2k
Jee Hyun An 180 414 66 313 34 1.0k

All Works

Loading papers...

Rankless by CCL
2026